Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
March 13, 2014
Comb Chem High Throughput Screen

Researchers at Emory disucss their high throughput research platforms and efforts to advance understanding of disease-related biology with its HTS/HCS platforms and chemical tools, in support of  drug discovery.

CTD²
March 01, 2014
Nature Reviews Clinical Oncology

A review of how a systems biology approach to cancer research can effect therapy development.

CTD²
March 01, 2014
Cold Spring Harbor Perspective in Medicine

Researchers screen for synthetic lethal interactions with MYC to identify possible routes for therapy.

CTD²
March 01, 2014
Nature Medicine

Researchers identify ARID1A-mutant cancer cells are dependent on ARID1B for survival, suggesting a potential therapeutic target.

CTD²
March 01, 2014
Cancer Discovery

Investigators used a novel mouse model to study genetic changes in prostate cancer.

CTD²
January 30, 2014
Cell Reports

The authors performed an image-based screen for genes regulating glioblastoma tumor-initiating cell maintenance and identified the transcription factor, ZFHX4, as a master regulator.

CTD²
January 21, 2014
Proceedings of the National Academy of Sciences

The researchers identified the GRB2-associated binding protein 2 (GAB2) as a recurrently amplified gene that potently transforms immortalized ovarian and fallopian tube secretory epithelial cells. 

CTD²
January 16, 2014
Cell

Glutathione peroxidase 4 regulates ferroptotic cancer cell death.

CTD²
January 15, 2014
Clinical Cancer Research

Investigators identified molecular players in response and resistance to combination chemotherapy and antiangiogenic drugs.

CTD²
January 13, 2014
Molecular and Cell Biology

Researchers discuss a role for SMARCA2 in oncogenesis caused by SMARCA4 loss and identify the ATPase and bromodomain-containing SMARCA2 as a potential therapeutic target in these cancers.

Pages

CSVXML